Lumakras Sales A Highlight Of Amgen’s Mixed Q3
Aimovig Down Sequentially And Year-Over-Year
While revenue beat consensus, the company slightly lowered its 2021 guidance due to pandemic impacts, but the closely watched KRAS G12C inhibitor exceeded expectations in its first full quarter.
You may also be interested in...
Last week, the Swiss major gave a glimpse into the next wave of innovation coming out of its labs in key areas such as osteoarthritis, pancreatic cancer and food allergy. Scrip has been taking a detailed look at the highlights.
The biotech could have the best-in-class KRAS inhibitor, but the departure of two senior executives has given investors the jitters as Mirati heads towards its first regulatory filing.
Adagrasib may carve out a niche as the superior drug in colorectal cancer, but lung cancer – where Lumakras already is approved – is a larger market where Amgen has a big lead.